JPWO2021118246A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021118246A5
JPWO2021118246A5 JP2022535140A JP2022535140A JPWO2021118246A5 JP WO2021118246 A5 JPWO2021118246 A5 JP WO2021118246A5 JP 2022535140 A JP2022535140 A JP 2022535140A JP 2022535140 A JP2022535140 A JP 2022535140A JP WO2021118246 A5 JPWO2021118246 A5 JP WO2021118246A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022535140A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506162A (ja
Publication date
Priority claimed from PCT/KR2019/018357 external-priority patent/WO2021132746A1/en
Application filed filed Critical
Priority claimed from PCT/KR2020/018029 external-priority patent/WO2021118246A1/en
Publication of JP2023506162A publication Critical patent/JP2023506162A/ja
Publication of JPWO2021118246A5 publication Critical patent/JPWO2021118246A5/ja
Pending legal-status Critical Current

Links

JP2022535140A 2019-12-10 2020-12-10 抗ｂｃｍａ／抗４－１ｂｂ二重特異性抗体及びその用途 Pending JP2023506162A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962945965P 2019-12-10 2019-12-10
US62/945,965 2019-12-10
KRPCT/KR2019/018357 2019-12-24
PCT/KR2019/018357 WO2021132746A1 (en) 2019-12-24 2019-12-24 Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
PCT/KR2020/018029 WO2021118246A1 (en) 2019-12-10 2020-12-10 Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023506162A JP2023506162A (ja) 2023-02-15
JPWO2021118246A5 true JPWO2021118246A5 (de) 2023-04-26

Family

ID=76330699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535140A Pending JP2023506162A (ja) 2019-12-10 2020-12-10 抗ｂｃｍａ／抗４－１ｂｂ二重特異性抗体及びその用途

Country Status (9)

Country Link
US (1) US20230051266A1 (de)
EP (1) EP4048700A4 (de)
JP (1) JP2023506162A (de)
KR (1) KR20220110753A (de)
CN (1) CN114829405A (de)
AU (1) AU2020400801A1 (de)
BR (1) BR112022011323A2 (de)
CA (1) CA3160765A1 (de)
WO (1) WO2021118246A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242247B2 (en) * 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
WO2015158671A1 (en) * 2014-04-14 2015-10-22 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
CN108350076B (zh) * 2015-08-17 2022-06-07 詹森药业有限公司 抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
EP3464362B1 (de) * 2016-05-27 2020-12-09 AbbVie Biotherapeutics Inc. Anti-4-1bb-antikörper und deren verwendungen

Similar Documents

Publication Publication Date Title
JP2019201643A5 (de)
HRP20201928T1 (hr) Kombinirana terapija bispecifičnom antigen vezujućom molekulom koja aktivira t-stanice, za cd3 i folatni receptor 1 (folr1), i antagonistom vezivanja osi pd-1
HRP20190605T1 (hr) Protutijela anti-fxi i postupci njihove uporabe
HRP20170374T1 (hr) Biološki proizvodi
RU2019141289A (ru) АНТИ-SIRPα АНТИТЕЛА
JP2021503455A5 (de)
JP2013091655A5 (de)
JP2018510636A5 (de)
JP2019501883A5 (de)
JP2006502699A5 (de)
JP2023134618A5 (de)
JP2018526981A5 (de)
CA3098415A1 (en) Anti-oxmif/anti-cd3 antibody for cancer treatment
JP2012532851A5 (de)
JP2010534478A5 (de)
JP2016503067A5 (de)
JP2024056687A5 (de)
JP2018522888A5 (de)
JP2020513759A5 (de)
FI3781200T3 (fi) Kelatoituneiden radionuklidien vasta-aineita
WO2022002033A1 (zh) 具有H2L2与HCAb结构的结合蛋白
Adair et al. Therapeutic antibodies
JP2024001073A5 (de)
JPWO2019165421A5 (de)
JPWO2020139926A5 (de)